
  • Services
    • THERAPEUTIC AREAS
      • Epilepsy & Seizure Disorders
      • Mental Illness
      • Neurodegenerative Disorders
      • Neurodevelopmental Disorders
      • Neuromuscular Disorders
      • Pain Models
      • Rare CNS Disorders
      • Injury and Trauma
    • CAPABILITIES
      • Microdyalisis
      • Biomarker Analysis
      • Pharmacokinetics & Pharmacodynamics (PK/PD)
      • Target Engagement
      • Electrophysiology
  • In Vivo AI Platforms
    • eCube™
    • NeuroCube®
    • PhenoCube®
    • SmartCube®
  • News & Insights
    • News
      • Press Releases
      • Upcoming Events
    • Insights
      • Publications
      • Posters
      • Research Updates
  • About
    • Leadership Team
    • Corporate Citizenship
    • Culture
    • Careers
  • Contact Us

Systematic behavioral evaluation of Huntington’s disease transgenic and knock-in mouse models.

by Desiree Cobb-Olori | May 20, 2009

Menalled, L.; El-Khodor, B. F.; Patry, M.; Suarez-Farinas, M.; Orenstein, S. J.; Zahasky, B.; Leahy, C.; Wheeler, V.; Yang, X. W.; MacDonald, M.; Morton, A. J.; Bates, G.; Leeds, J.; Park, L.; Howland, D.; Signer, E.; Tobin, A.; Brunner, D Neurobiol Dis 2009, 35,...

GABAa receptor α1 subunit (Gabra1) knockout mice: review and new results. In Mutant and Transgenic Tools in Modeling Brain Disorders

by Desiree Cobb-Olori | Mar 20, 2009

Ye, G-L.; Baker, K.B.; Mason, S.M.; Zhang, W.; Kirkpatrick, L.; Lanthorn, T.H.; Savelieva, K.V. Kalueff, AV; Bergner, CL, Ed. Humana Press: 2009, 65-90.

Loss of the putative catalytic domain of HDAC4 leads to reduced thermal nociception and seizures while allowing normal bone development.

by Desiree Cobb-Olori | Jan 31, 2009

Rajan, I.; Savelieva, K.V.; Ye, G-L.; Wang, C-Y.; Malbari, M. M.; Friddle, C.; Lanthorn, T.H.; Zhang, W. PLoS One 2009, 4(8), e6612.

Translational aspects of pharmacological research into anxiety disorders: the stress-induced hyperthermia (SIH) paradigm.

by Desiree Cobb-Olori | Dec 12, 2008

Vinkers, C. H.; van Bogaert, M. J.; Klanker, M.; Korte, S. M.; Oosting, R.; Hanania, T.; Hopkins, S. C.; Olivier, B.; Groenink, L. Eur J Pharmacol 2008, 585, 407-25.

Cognitive endpoints as disease biomarkers: optimizing the congruency of preclinical models to the clinic.

by Desiree Cobb-Olori | Dec 5, 2008

Day, M.; Balci, F.; Wan, H. I.; Fox, G. B.; Rutkowski, J. L.; Feuerstein, G. Curr Opin Investig Drugs 2008, 9, 696-706.
« Older Entries
Next Entries »
  • Therapeutic Areas
    • Epilepsy & Seizure Disorders
      • Preclinical Seizure Models
        • Chemical Induction Models
        • Electroshock-Induced Seizures
        • Amygdala-Induced Kindling
        • Harmaline-Induced Tremors
      • Dravet Syndrome
      • EEG Seizure
      • Angelman Syndrome
      • Rett Syndrome
      • Tuberous Sclerosis
    • Mental Illness
      • Anxiety
      • Depression
      • Schizophrenia
      • ADHD
      • Drug Abuse Liability
    • Neurodegenerative Disorders
      • Alzheimer’s Disease
      • Amyotrophic Lateral Sclerosis
      • Huntington’s Disease
      • Parkinson’s Disease
      • Spinal Muscular Atrophy (SMA)
    • Neurodevelopmental Disorders
      • ADHD Studies
      • Angelman Syndrome
      • Autism Spectrum Disorder
      • Fragile X Syndrome
      • Rett Syndrome
    • Neuromuscular Disorders
      • Amyotrophic Lateral Sclerosis
      • Charcot Marie Tooth Disease
      • Duchenne Muscular Dystrophy
      • Spinal Muscular Atrophy (SMA)
    • Pain Models
      • Acute Pain
      • Inflammatory Pain
      • Neuropathic Pain -Nerve Ligation
      • Osteoarthritis Pain Studies
      • Postoperative Pain Studies
      • PSPP Program
      • Visceral Pain
    • Rare CNS Disorders
      • Angelman Syndrome
      • Charcot Marie Tooth Disease
      • Dravet Syndrome
      • Fragile X Syndrome
      • Gaucher Disease
      • Rett Syndrome
      • Tuberous Sclerosis (TSC) Preclinical Research
    • Injury and Trauma
      • Spinal Cord Injury
      • Traumatic Brain Injury
  • Capabilities
    • Microdyalisis
    • Biomarker Analysis
      • Immunohistochemistry
      • Molecular Pharmacology
    • Pharmacokinetics & Pharmacodynamics (PK/PD)
    • Target Engagement
      • Receptor Occupancy
    • Electrophysiology
      • In vivo electrophysiology
      • Ex vivo electrophysiology
      • Compound Muscle Action Potention

Let’s Find the Right Solution Together

Our scientists are here to help you find the right model or capability for your program.

Request a Consultation

Quick Links

  • Services
  • In Vivo AI Platforms
  • News & Insights
  • About
  • Contact

Contact

Address

215 College Road
Paramus, NJ 07652

Email

info@psychogenics.com

Phone

(914) 406-8019

Fax

(914) 406-8090

© 2026 PsychoGenics Inc. All rights reserved.

  • Privacy Policy
  • Terms of Use
  • Financial Conflict of Interest Policy
  • Sitemap
  • Webmaster
Manage Consent
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Functional Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
  • Manage options
  • Manage services
  • Manage {vendor_count} vendors
  • Read more about these purposes
View preferences
  • {title}
  • {title}
  • {title}
Manage Consent
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Functional Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
  • Manage options
  • Manage services
  • Manage {vendor_count} vendors
  • Read more about these purposes
View preferences
  • {title}
  • {title}
  • {title}